FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

13 letters match. Newest first.

  1. TSP Solutions Pte. Ltd.

    FDA warns Singapore OTC drug maker TSP Solutions over missing release testing and component identity checks for sunscreens.

    High risk
  2. TCI Co., Ltd BioCosme PABP BRANCH

    FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.

    High risk
  3. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk
  4. AHC Products, Inc.

    AHC Products, Inc. was cited for manufacturing-rule violations and unapproved animal drugs, including AniPrin and Rot-B-Gone.

    High risk
  5. Foshan Miwei Cosmetics Co., Ltd.

    FDA warns Foshan Miwei Cosmetics over manufacturing practice failures and unapproved, misbranded over-the-counter (OTC) sunscreen drugs; drugs on import alert.

    High risk
  6. Lexia LLC

    FDA cited Lexia for manufacturing violations in an OTC topical pain relief drug, including missing release and component testing.

    High risk
  7. Pro Numb Tattoo Numbing Spray, LLC

    FDA cited Pro Numb Tattoo Numbing Spray for selling unapproved, misbranded numbing drugs and manufacturing quality failures after a November 2025 inspection.

    High risk
  8. Yangzhou H&R Plastic Daily Chemical Co., Ltd.

    Yangzhou H&R Plastic Daily Chemical, a Chinese contract manufacturer, lacked release testing and CGMP controls for its OTC drug.

    High risk
  9. OraLabs, Inc.

    FDA warned OraLabs, an OTC drugmaker in Parker, Colorado, that it skipped microbial release testing and dismissed contamination findings.

    High risk
  10. A. Nelson & Co. Ltd.

    London homeopathic drug maker A. Nelson & Co. shipped children's products without microbial testing and discarded quality records.

    High risk
  11. Cosmetic Manufacturers Pty Ltd.

    FDA warned Cosmetic Manufacturers Pty Ltd. that its Australian drug site was adulterated due to CGMP violations and placed its drugs on import alert.

    High risk
  12. Signature Formulations, LLC

    FDA says Signature Formulations made OTC drugs on shared equipment without adequate controls, risking hormone contamination.

    High risk
  13. Abbott Diabetes Care, Inc.

    FDA warns Abbott Diabetes Care that FreeStyle Libre 3 glucose monitors lacked design transfer and finished-device accuracy release testing.

    High risk